Michael Castagna

Michael Castagna is the Chief Executive Officer of MannKind Corporation since March 2016, overseeing products such as Afrezza Inhaled Insulin, V-GO, and Tyvaso DPI. Prior to this role, Castagna served as Vice President in various capacities at Amgen from November 2012 to March 2016, focusing on the biosimilar business and lifecycle management. Castagna's experience includes significant leadership positions at Bristol-Myers Squibb, Sandoz, Merck Serono, and Pharmasset, where roles encompassed medical, marketing, and sales. Michael Castagna holds a Doctor of Pharmacy (PharmD) from Massachusetts College of Pharmacy and Health Sciences, an MBA in Entrepreneurial from The Wharton School, and a BS in Pharmacy from the University of the Sciences in Philadelphia.